JCAR017

Phase 2Small molecule

JCAR017 is one of 46 small molecule programs targeting Leukemia, Lymphocytic, Chronic, B-Cell. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia, Lymphocytic, Chronic, B-CellActive, not recruiting

LymphomaCompleted

Leukemia, Lymphocytic, Chronic, B-CellPreclinical

Active, not recruiting

LymphomaPhase 2

Completed

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

JCAR017

Bristol-Myers Squibb

Phase 2

3 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03331198

Q3 2031

Phase 2Active, not recruiting

Lymphoma

NCT04245839

Clinical

Trials by Indication[1]

Lymphoma3 trials

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02631044·387 enrolled

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03484702·113 enrolled

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04245839·276 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03743246·21 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT03331198·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for JCAR017. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JCAR017 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JCAR017. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

JCAR017

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2031

Trials by Indication[1]

Lymphoma3 trials

Relapsed/Refractory B-cell Malignancies1 trial

B-cell acute lymphoblastic leukemia1 trial

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

References

Drug Info

Quick Facts

Related News